CL2018000002A1 - Agente terapéutico y método para tratar el síndrome de hunter. - Google Patents
Agente terapéutico y método para tratar el síndrome de hunter.Info
- Publication number
- CL2018000002A1 CL2018000002A1 CL2018000002A CL2018000002A CL2018000002A1 CL 2018000002 A1 CL2018000002 A1 CL 2018000002A1 CL 2018000002 A CL2018000002 A CL 2018000002A CL 2018000002 A CL2018000002 A CL 2018000002A CL 2018000002 A1 CL2018000002 A1 CL 2018000002A1
- Authority
- CL
- Chile
- Prior art keywords
- week
- patient
- injection
- once
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UN AGENTE TERAPÉUTICO DEL SÍNDROME DE HUNTER Y, MÁS ESPECÍFICAMENTE, A UN AGENTE TERAPÉUTICO DEL SÍNDROME DE HUNTER, QUE PUEDE REDUCIR EL NÚMERO DE VISITAS AL HOSPITAL POR PACIENTES CON EL SÍNDROME DE HUNTER A DOS VECES AL MES O MENOS AL CONTENER UNA PRIMERA COMPOSICIÓN PARA SER INYECTADA POR VÍA INTRAVENOSA Y UNA SEGUNDA COMPOSICIÓN INYECTADA POR VÍA SUBCUTÁNEA, QUE PRESENTA UN EFECTO MEDICINAL EQUIVALENTE O MAYOR AL DE UNA INYECCIÓN INTRAVENOSA CONVENCIONAL UNA VEZ A LA SEMANA, AUMENTA EL CUMPLIMIENTO DE LA TOMA DE FÁRMACOS POR PARTE DE LOS PACIENTES EN COMPARACIÓN CON LOS AGENTES TERAPÉUTICOS CONVENCIONALES Y LOS MÉTODOS DE TRATAMIENTO, Y PERMITE UN MAYOR BIENESTAR Y CONVENIENCIA PARA EL PACIENTE. EL MÉTODO DE CO-INYECCIÓN IV / SC DE ACUERDO CON LA PRESENTE INVENCIÓN EXHIBE UN EFECTO TERAPÉUTICO EQUIVALENTE O SUPERIOR COMPARADO CON EL DE UNA INYECCIÓN IV CONVENCIONAL UNA VEZ A LA SEMANA, AL TIEMPO QUE PERMITE A UN PACIENTE VISITAR EL HOSPITAL CON UNA FRECUENCIA MENOR A UNA VEZ A LA SEMANA, COMO EN VISITAS CONVENCIONALES, REEMPLAZANDO EL MÉTODO CONVENCIONAL DE INYECCIÓN INTRAVENOSA UNA VEZ A LA SEMANA, QUE REQUIERE QUE EL PACIENTE VISITE EL HOSPITAL UNA VEZ A LA SEMANA, CON INYECCIONES SC MEDIANTE LAS CUALES UN NÚMERO PREDETERMINADO DE VECES ENTRE INYECCIONES IV PUEDEN REALIZARSE DIRECTAMENTE EN CASA POR EL CUSTODIO DEL PACIENTE. ESTO VA EN CONTRA DE UN CONCEPTO CONVENCIONAL DE QUE EL EFECTO TERAPÉUTICO LOGRADO POR UNA INYECCIÓN SC NO SERÍA SUPERIOR AL EFECTO TERAPÉUTICO LOGRADO POR UNA INYECCIÓN IV. POR LO TANTO, LA PRESENTE INVENCIÓN SE REFIERE A UN AGENTE TERAPÉUTICO Y A UN MÉTODO DE TRATAMIENTO CUYO EFECTO DEL TRATAMIENTO DEL SÍNDROME DE HUNTER MEJORA DRAMÁTICAMENTE SOBRE EL DE UNA TECNOLOGÍA CONVENCIONAL.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187867P | 2015-07-02 | 2015-07-02 | |
| KR1020150187297A KR20170004814A (ko) | 2015-07-02 | 2015-12-28 | 헌터증후군 치료제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000002A1 true CL2018000002A1 (es) | 2018-06-29 |
Family
ID=57833331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000002A CL2018000002A1 (es) | 2015-07-02 | 2018-01-02 | Agente terapéutico y método para tratar el síndrome de hunter. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10561713B2 (es) |
| EP (1) | EP3318267B1 (es) |
| JP (2) | JP6606199B2 (es) |
| KR (3) | KR20170004814A (es) |
| CN (1) | CN107921091A (es) |
| BR (1) | BR112018000051A2 (es) |
| CA (1) | CA2990370C (es) |
| CL (1) | CL2018000002A1 (es) |
| CO (1) | CO2018000196A2 (es) |
| EA (1) | EA038110B1 (es) |
| ES (1) | ES2866957T3 (es) |
| HK (1) | HK1252663A1 (es) |
| MX (1) | MX2017016302A (es) |
| PE (1) | PE20190351A1 (es) |
| PL (1) | PL3318267T3 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102603915B1 (ko) | 2015-07-02 | 2023-11-21 | 에프. 호프만-라 로슈 아게 | 이환형 락탐 및 이의 사용 방법 |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| KR102671857B1 (ko) | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| CA3116004A1 (en) * | 2018-10-11 | 2020-04-16 | Indivior Uk Limited | Buprenorphine to treat respiratory depression |
| US11857641B2 (en) * | 2019-02-06 | 2024-01-02 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
| CN115916244A (zh) | 2020-06-16 | 2023-04-04 | 新型医药公司 | 用于治疗戊二酸尿症的组合物及其给药方法 |
| WO2024144003A1 (ko) * | 2022-12-29 | 2024-07-04 | 주식회사 녹십자 | 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2423233B1 (en) | 2009-04-22 | 2015-03-11 | Alteogen, Inc | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| KR102663407B1 (ko) * | 2010-06-25 | 2024-05-10 | 샤이어 휴먼 지네틱 테라피즈 인크. | 치료제들의 cns 전달 |
| MX2020001395A (es) | 2010-06-25 | 2022-03-24 | Shire Human Genetic Therapies | Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central. |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| WO2013096912A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| WO2013148277A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate- 2-sulfatase |
| JP2015013624A (ja) * | 2013-07-08 | 2015-01-22 | 船井電機株式会社 | 手動推進器具 |
-
2015
- 2015-12-28 KR KR1020150187297A patent/KR20170004814A/ko not_active Application Discontinuation
-
2016
- 2016-07-04 KR KR1020187001448A patent/KR20180015256A/ko active Search and Examination
- 2016-07-04 US US15/738,017 patent/US10561713B2/en active Active
- 2016-07-04 CA CA2990370A patent/CA2990370C/en active Active
- 2016-07-04 PL PL16818303T patent/PL3318267T3/pl unknown
- 2016-07-04 PE PE2017002893A patent/PE20190351A1/es unknown
- 2016-07-04 CN CN201680038666.3A patent/CN107921091A/zh active Pending
- 2016-07-04 BR BR112018000051-5A patent/BR112018000051A2/pt active Search and Examination
- 2016-07-04 KR KR1020197036839A patent/KR102213055B1/ko active IP Right Grant
- 2016-07-04 JP JP2017568199A patent/JP6606199B2/ja active Active
- 2016-07-04 ES ES16818303T patent/ES2866957T3/es active Active
- 2016-07-04 EA EA201890182A patent/EA038110B1/ru unknown
- 2016-07-04 MX MX2017016302A patent/MX2017016302A/es unknown
- 2016-07-04 EP EP16818303.6A patent/EP3318267B1/en active Active
-
2018
- 2018-01-02 CL CL2018000002A patent/CL2018000002A1/es unknown
- 2018-01-11 CO CONC2018/0000196A patent/CO2018000196A2/es unknown
- 2018-09-18 HK HK18111970.1A patent/HK1252663A1/zh unknown
-
2019
- 2019-09-05 JP JP2019161855A patent/JP6858231B2/ja active Active
- 2019-11-27 US US16/698,403 patent/US20200093899A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2990370A1 (en) | 2017-01-05 |
| EP3318267A4 (en) | 2019-02-27 |
| PE20190351A1 (es) | 2019-03-07 |
| KR20170004814A (ko) | 2017-01-11 |
| KR20180015256A (ko) | 2018-02-12 |
| JP6858231B2 (ja) | 2021-04-14 |
| EP3318267A1 (en) | 2018-05-09 |
| BR112018000051A2 (pt) | 2018-09-04 |
| US10561713B2 (en) | 2020-02-18 |
| CO2018000196A2 (es) | 2018-03-28 |
| JP6606199B2 (ja) | 2019-11-13 |
| KR102213055B1 (ko) | 2021-02-08 |
| KR20190141026A (ko) | 2019-12-20 |
| CN107921091A (zh) | 2018-04-17 |
| EA038110B1 (ru) | 2021-07-07 |
| PL3318267T3 (pl) | 2021-07-12 |
| MX2017016302A (es) | 2018-03-23 |
| US20180303914A1 (en) | 2018-10-25 |
| JP2018519326A (ja) | 2018-07-19 |
| CA2990370C (en) | 2022-05-17 |
| EA201890182A1 (ru) | 2018-06-29 |
| US20200093899A1 (en) | 2020-03-26 |
| JP2020019775A (ja) | 2020-02-06 |
| HK1252663A1 (zh) | 2019-05-31 |
| ES2866957T3 (es) | 2021-10-20 |
| EP3318267B1 (en) | 2021-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| AR076718A1 (es) | Modulo medicinal con seleccion del usuario | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
| BR112015023007A8 (pt) | dispositivo de injeção de múltiplas câmaras | |
| MX2021004546A (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
| BR112018016341A2 (pt) | solução de bloqueio do cateter e terapia de bloqueio do cateter | |
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| BR112018000067A2 (pt) | dispositivo de liberação de uso único previamente preenchido com um agente reconstituível | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| EA201990228A1 (ru) | Система инъекции имплантата/медикамента на основе защитного корпуса | |
| BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| BR112016028177A2 (pt) | seringa | |
| UY36537A (es) | Método de uso de la respuesta al anticuerpo antiacetato de glatirámero | |
| Bordbar et al. | The challenge of chemotherapy extravasations | |
| JP1678733S (ja) | 薬剤投与デバイス | |
| JP1675942S (ja) | 薬剤投与デバイス | |
| JP1675944S (ja) | 薬剤投与デバイス | |
| JP1675945S (ja) | 薬剤投与デバイス | |
| JP1676041S (ja) | 薬剤投与デバイス |